A pattern emerging from years of national health surveys invites a question medicine has rarely thought to ask: might substances long confined to the margins of pharmacology hold some quiet benefit for the human heart? Researchers examining data from tens of thousands of Americans found that those who had used classic psychedelics reported lower rates of heart disease, high blood pressure, and diabetes — a correlation modest in certainty but significant enough in implication to warrant serious scientific attention. The finding does not prove that psychedelics heal, only that the relationship b
Psychedelics May Offer Unexpected Cardiovascular Benefits, Early Research Suggests
The direction of causality remains unknown.
Mark
So people who've used psychedelics report better heart health. That's the finding?
Mimi
That's what the data showed, yes. Lower odds of heart disease, high blood pressure, diabetes—even after controlling for a lot of other factors.
Luke
But we don't know if the psychedelics caused it, right? Or if healthier people are just more likely to try them?
Mimi
Exactly. The researchers were clear about that. Causality is still unknown.
Mark
What are the actual mechanisms they think might be at work?
Mimi
A few possibilities. Psychedelics improve mental health, and mental health is tied to heart health. Or the receptors they activate in the brain also affect cardiometabolic function. Or they have anti-inflammatory properties.
Luke
Those are three different stories. Do we have evidence for any of them?
Mimi
Some. Animal studies show related drugs improve glucose tolerance. Ayahuasca shows anti-inflammatory effects. But none of this has been tested in controlled human trials yet.
Mark
So what's the next step?
Mimi
Double-blind, randomized, placebo-controlled trials. That's what the researchers are calling for.
Luke
And until then, we're looking at an interesting correlation that could mean almost anything.
Mimi
That's fair. But it's interesting enough to investigate further.
The Pulse
- A striking pattern in U.S. national health data shows psychedelic users consistently reporting lower rates of heart disease and diabetes — even after controlling for age, income, race, and lifestyle factors.
- The core tension is epistemological: the data cannot tell us whether psychedelics protect the heart, or whether healthier people simply tend to use them more.
- Biological plausibility keeps the question alive — serotonin receptors tied to cardiometabolic function, anti-inflammatory properties in substances like ayahuasca, and the well-documented link between mental health and cardiovascular risk all suggest mechanisms worth testing.
- Scientists are calling for the gold standard — double-blind, randomized, placebo-controlled trials — to move this signal out of the realm of correlation and into something medicine can act on.
A pattern emerging from years of national health surveys invites a question medicine has rarely thought to ask: might substances long confined to the margins of pharmacology hold some quiet benefit for the human heart? Researchers examining data from tens of thousands of Americans found that those who had used classic psychedelics reported lower rates of heart disease, high blood pressure, and diabetes — a correlation modest in certainty but significant enough in implication to warrant serious scientific attention. The finding does not prove that psychedelics heal, only that the relationship between mind-altering experience and bodily health may be more entangled than convention has allowed.
For years, a curious thread has run through psychedelic research: people who use these substances tend to report better health outcomes. Magic mushrooms earned a breakthrough therapy designation for depression, MDMA-assisted therapy edged toward approval for PTSD, and LSD showed early promise for pain. Now researchers are asking whether the benefits might extend to the heart.
Analyzing data from the U.S. National Survey on Drug Use and Health — first from a single year, then across a decade from 2005 to 2014 — scientists found that people who had used classic psychedelics at least once reported lower rates of heart disease, high blood pressure, and diabetes. The association held even after accounting for age, gender, income, education, and other drug use. The pattern was consistent enough to take seriously.
But the researchers, including Oxford's Otto Simonsson, were candid about what the data cannot show. Causality remains unknown. Healthier people may simply be more likely to use psychedelics, or some unmeasured third factor could explain both. What looks like a signal might still be noise.
The biological pathways, however, offer genuine reason for curiosity. Psychedelics activate serotonin receptors connected to cardiometabolic function. Related compounds have improved glucose tolerance in animal models of diabetes. Substances like ayahuasca carry anti-inflammatory properties associated with heart health. And if psychedelics improve mental health — as early evidence suggests — they may be protecting the cardiovascular system indirectly, given how tightly depression and anxiety are linked to heart disease.
What the field needs now is rigorous controlled trials. The early signals are real, but the mystery of how — or whether — psychedelics actually benefit the heart remains largely unsolved, and worth pursuing.
For years, researchers have been chasing a curious thread: people who have used psychedelics seem to report better health outcomes than those who haven't. Magic mushrooms earned a 'breakthrough therapy' designation for depression. LSD showed promise for pain management. MDMA-assisted therapy inched closer to legal approval for treating post-traumatic stress disorder. Now scientists are asking whether these substances might offer something unexpected—protection for the heart.
In early 2021, researchers analyzing data from the United States National Survey on Drug Use and Health noticed a pattern. People who had tried a classic psychedelic at least once—whether DMT, ayahuasca, LSD, mescaline, peyote, or psilocybin—reported higher overall health and lower rates of being overweight. More striking, they had lower odds of having experienced heart conditions like high blood pressure in the past year. The finding was intriguing enough that the team dug deeper, pulling data spanning 2005 to 2014 from the same national survey. Again, the pattern held: lifetime psychedelic users showed lower odds of heart disease and diabetes in the previous year, even after the researchers accounted for age, gender, marital status, race, household income, education level, risky behavior, and other drug use.
But correlation is not causation, and the researchers know it. Otto Simonsson from the University of Oxford was direct about the limitation: the direction of causality remains unknown. It's possible that psychedelic use itself improves cardiovascular health. It's equally possible that people in better cardiovascular health are more likely to use psychedelics. Or some third factor—an unmeasured variable, a shared predisposition toward healthy behaviors—could explain both. The authors acknowledged this plainly in their analysis, noting that latent variables not captured in the dataset could have shaped the results. What looks like a signal might be noise.
Still, there are plausible biological mechanisms worth exploring. Depression, anxiety, and other mental health conditions are tightly linked to cardiovascular disease. If psychedelics improve mental health—and early evidence suggests they do—they might be protecting the heart indirectly. The receptors that psychedelics activate in the brain are also connected to cardiometabolic health. Other drugs that bind to these same serotonin receptors have shown improved glucose tolerance in animal models of obesity and type 2 diabetes. Additionally, some classic psychedelics like ayahuasca appear to have anti-inflammatory and immunomodulatory properties, both of which are associated with better heart health.
None of this is settled. The current analysis is limited in what it can actually prove. Researchers emphasize that future work requires the gold standard: double-blind, randomized, placebo-controlled trials that can establish whether psychedelic use actually reduces the risk of cardiometabolic disease and, if it does, through which specific mechanisms. The potential long-term cardiovascular effects of psychedelics remain largely mysterious. But the mystery is worth pursuing, and the early signals are real enough to justify the next phase of investigation.
Notable Quotes
The direction of causality remains unknown. Future trials with double-blind, randomized, placebo-controlled designs are needed to establish whether classic psychedelic use may reduce the risk of cardiometabolic diseases.— Otto Simonsson, University of Oxford
Want the full story?
Read the original at ScienceAlert ↗
Health & Medicine